术前治疗对肝细胞癌患者行肝移植术后生存的影响
Effect of Preoperative Treatment on Survival of Patients with Hepatocellular Carcinoma after Liver Transplantation
DOI: 10.12677/ACM.2023.133411, PDF,    科研立项经费支持
作者: 胡宁宁, 王胜亮, 王 栋, 赵延荣, 蔡金贞, 郭 源*:青岛大学附属医院肝移植中心肝脏外科,山东 青岛;于建智:胜利油田中心医院胸外科,山东 东营
关键词: 肝细胞癌肝移植术前治疗预后分析Hepatocellular Carcinoma Liver Transplantation Preoperative Treatment Prognosis Analysis
摘要: 目的:探讨术前治疗对肝细胞癌(HCC)肝移植患者生存预后的影响。方法:回顾性研究2019年01月至2019年12月31于青岛大学附属医院器官移植中心因肝细胞癌(HCC)行肝移植治疗的58名肝移植患者临床资料。根据术前是否行术前治疗,分对照组(n = 32),处理组(n = 26)。比较对照组和处理组的临床资料,分析肝癌肝移植患者的预后及危险因素。结果:本研究共纳入58例肝癌肝移植患者,男性病人54例,中位随访时间27.8月,至随访结束,26例患者出现肿瘤复发,复发率为44.8%,17例患者死亡,死亡率为29.3%,研究发现术前治疗可显著提高肝移植术后患者PFS和OS,差异有统计学意义(均为P < 0.05)。单因素及多因素Cox回归分析显示,肿瘤最大直径 > 5 cm,肝被膜侵犯是影响肝癌肝移植患者术后PFS的独立危险因素,术前治疗和肝被膜侵犯是影响肝癌肝移植患者术后OS的独立危险因素,(均为P < 0.05)。结论:肝癌肝移植患者术前治疗可以显著减少术后复发,提高术后的生存时间。
Abstract: Objective: To investigate the effect of preoperative treatment on the survival and prognosis of pa-tients with hepatocellular carcinoma undergoing liver transplantation. Methods: The clinical data of 58 patients with hepatocellular carcinoma (HCC) who underwent liver transplantation in the Organ Transplantation Center of affiliated Hospital of Qingdao University from January 2019 to December 2019 were studied retrospectively. According to the preoperative treatment, the patients were di-vided into control group (n = 32) and treatment group (n = 26). The clinical data of the control group and the treatment group were compared, and the prognosis and risk factors of liver cancer patients undergoing liver transplantation were analyzed. Results: A total of 58 liver cancer patients and 54 male patients were included in this study. The median follow-up period was 27.8 months to the end of follow-up, 26 patients had tumor recurrence, the recurrence rate was 44.8%, 17 patients died, and the mortality rate was 29.3%. It was found that preoperative treatment could significant-ly improve the PFS and OS of patients after liver transplantation, and the difference was statistically significant (all P < 0.05). Univariate and multivariate Cox regression analysis showed that the maximum diameter of tumor > 5 cm and liver capsule invasion were independent risk factors for PFS after liver transplantation. Preoperative treatment and liver capsule invasion were independ-ent risk factors for OS after liver transplantation (all P < 0.05). Conclusions: Preoperative treatment of liver cancer patients undergoing liver transplantation can significantly reduce postoperative re-currence and improve postoperative survival time.
文章引用:胡宁宁, 于建智, 王胜亮, 王栋, 赵延荣, 蔡金贞, 郭源. 术前治疗对肝细胞癌患者行肝移植术后生存的影响[J]. 临床医学进展, 2023, 13(3): 2903-2910. https://doi.org/10.12677/ACM.2023.133411

参考文献

[1] Sung, H., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2022年版) [J]. 中华外科杂志, 2022, 21(2): 143-168.
[3] Ogawa, K. and Takada, Y. (2022) Role of Pretransplant Treatments for Patients with Hepatocellular Carcinoma Waiting for Liver Transplantation. Cancers (Basel), 14, 396. [Google Scholar] [CrossRef] [PubMed]
[4] Marrero, J.A., et al. (2018) Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepa-tology, 68, 723-750. [Google Scholar] [CrossRef] [PubMed]
[5] European Association for the Study of the Liver (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236.
[6] Park, J.W., et al. (2015) Global Patterns of Hepatocellular Carcinoma Management from Diagnosis to Death: The BRIDGE Study. Liver International, 35, 2155-2166. [Google Scholar] [CrossRef] [PubMed]
[7] Ward, E.M., et al. (2021) Clinical Out-comes of Ablation Compared with Resection for Single Hepatocellular Carcinoma Lesions, as a Primary Treatment or Bridging to Liver Transplantation: A Retrospective Comparative Study. Annals of Transplantation, 26, e931980. [Google Scholar] [CrossRef
[8] Sun, H.C., et al. (2022) Chinese Expert Consensus on Conversion Therapy for Hepatocellular Carcinoma (2021 Edition). The Hepatobiliary Surgery and Nutrition, 11, 227-252. [Google Scholar] [CrossRef] [PubMed]
[9] Affonso, B.B., et al. (2019) Long-Term Outcomes of Hepatocellular Carcinoma That Underwent Chemoembolization for Bridging or Downstaging. World Journal of Gastroenterology, 25, 5687-5701. [Google Scholar] [CrossRef] [PubMed]
[10] Pavel, M.C. and Fuster, J. (2018) Expansion of the Hepatocellular Carcinoma Milan Criteria in Liver Transplantation: Future Directions. World Journal of Gastroenterology, 24, 3626-3636. [Google Scholar] [CrossRef] [PubMed]
[11] Yao, F.Y., et al. (2015) Downstaging of Hepatocellular Cancer before Liver Transplant: Long-Term Outcome Compared to Tumors within Milan Criteria. Hepatology, 61, 1968-1977. [Google Scholar] [CrossRef] [PubMed]
[12] 中国医师协会器官移植医师分会. 中国肝癌肝移植临床实践指南(2021版) [J]. 中华移植杂志(电子版), 2021, 15(6): 321-328.
[13] Mazzaferro, V., et al. (1996) Liver Trans-plantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis. The New England Journal of Medicine, 334, 693-700. [Google Scholar] [CrossRef
[14] Tabrizian, P., et al. (2019) A US Multicenter Analysis of 2529 HCC Patients Undergoing Liver Transplantation: 10-Year Outcome Assessing the Role of Down-Staging to within Milan Criteria. Hepatology, 70, 10-11.
[15] Franssen, B., et al. (2014) Actual 10-Year Survival Following Hepatectomy for Hepatocellular Carcinoma. HPB (Oxford), 16, 830-835. [Google Scholar] [CrossRef] [PubMed]
[16] Yao, F.Y., et al. (2001) Liver Transplantation for Hepatocellular Carcinoma: Expansion of the Tumor Size Limits Does Not Adversely Impact Survival. Hepatology, 33, 1394-1403. [Google Scholar] [CrossRef] [PubMed]
[17] Mazzaferro, V., et al. (2009) Predicting Survival after Liver Trans-plantation in Patients with Hepatocellular Carcinoma Be Yond the Milan Criteria: A Retrospective, Exploratory Analysis. The Lancet Oncology, 10, 35-43.
[18] Mazzaferro, V., et al. (2018) Metroticket 2.0 Model for Analysis of Competing Risks of Death after Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology, 154, 128-139. [Google Scholar] [CrossRef] [PubMed]
[19] 樊嘉, 周俭, 徐泱, 等. 肝癌肝移植适应证的选择: 上海复旦标准[J]. 中华医学杂志, 2006, 86(18): 1227-1231.
[20] Zheng, S.S., et al. (2008) Liver Transplantation for Hepato-cellular Carcinoma: Hangzhou Experiences. Transplantation, 85, 1726-1732. [Google Scholar] [CrossRef
[21] Galle, P.R., et al. (2018) EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. Journal of Hepatology, 69, 182-236. [Google Scholar] [CrossRef] [PubMed]
[22] Tan, C.H.N., et al. (2018) Bridging Therapies to Liver Transplanta-tion for Hepatocellular Carcinoma: A Bridge to Nowhere? Annals of Hepato-Biliary-Pancreatic Surgery, 22, 27-35. [Google Scholar] [CrossRef] [PubMed]
[23] Clavien, P.-A., et al. (2012) Recommendations for Liver Trans-plantation for Hepatocellular Carcinoma: An International Consensus Conference Report. The Lancet Oncology, 13, e11-e22. [Google Scholar] [CrossRef